




Searching News Database: risperidone
HSMN NewsFeed - 27 Jun 2019
DURECT Announces Submission to FDA of a Full Response to the POSIMIR(R) Complete Response Letter
DURECT Announces Submission to FDA of a Full Response to the POSIMIR(R) Complete Response Letter
HSMN NewsFeed - 28 May 2018
Luye Pharma Acquires AstraZeneca's Signature Products Seroquel and Seroquel XR
Luye Pharma Acquires AstraZeneca's Signature Products Seroquel and Seroquel XR
HSMN NewsFeed - 2 Dec 2013
Forest to Acquire U.S. Marketing Rights to Saphris(R) (asenapine) from Merck
Forest to Acquire U.S. Marketing Rights to Saphris(R) (asenapine) from Merck
HSMN NewsFeed - 8 Nov 2012
Zogenix Announces FDA Advisory Committee Review of Zohydro(TM) ER for the Management of Chronic Pain
Zogenix Announces FDA Advisory Committee Review of Zohydro(TM) ER for the Management of Chronic Pain
HSMN NewsFeed - 16 Sep 2008
Mylan Receives FDA Approval for Generic Version of Anti-Psychotic Risperdal(R)
Mylan Receives FDA Approval for Generic Version of Anti-Psychotic Risperdal(R)
HSMN NewsFeed - 28 Jul 2008
FDA Issues Not Approvable Letter for Iloperidone to Vanda Pharmaceuticals
FDA Issues Not Approvable Letter for Iloperidone to Vanda Pharmaceuticals
HSMN NewsFeed - 28 Jul 2008
Vanda Pharmaceuticals Announces Receipt of Not Approvable Letter From FDA for Iloperidone
Vanda Pharmaceuticals Announces Receipt of Not Approvable Letter From FDA for Iloperidone
HSMN NewsFeed - 13 Dec 2007
Iloperidone Phase III Clinical Data Demonstrate Efficacy and Favorable Safety and Tolerability Profile
Iloperidone Phase III Clinical Data Demonstrate Efficacy and Favorable Safety and Tolerability Profile
HSMN NewsFeed - 14 Nov 2007
Study Shows Organon's Asenapine Demonstrates Efficacy and Tolerability in Treating Acute Schizophrenia
Study Shows Organon's Asenapine Demonstrates Efficacy and Tolerability in Treating Acute Schizophrenia
HSMN NewsFeed - 27 Apr 2007
FDA Approves INVEGA (TM) for Long-Term Maintenance Treatment of Schizophrenia
FDA Approves INVEGA (TM) for Long-Term Maintenance Treatment of Schizophrenia
HSMN NewsFeed - 25 Apr 2007
Alkermes and Indevus Announce Initiation of Phase 2a Clinical Study of ALKS 27 for the Treatment of COPD
Alkermes and Indevus Announce Initiation of Phase 2a Clinical Study of ALKS 27 for the Treatment of COPD
HSMN NewsFeed - 13 Apr 2007
FDA Approves New Dose of RISPERDAL(R) CONSTA(R) for Schizophrenia Treatment
FDA Approves New Dose of RISPERDAL(R) CONSTA(R) for Schizophrenia Treatment
HSMN NewsFeed - 20 Dec 2006
Alkermes Announces Submission of New Drug Application for RISPERDAL(R) CONSTA(R) in Japan
Alkermes Announces Submission of New Drug Application for RISPERDAL(R) CONSTA(R) in Japan
HSMN NewsFeed - 1 Dec 2006
Lilly Responds to the Cost-Effectiveness Analysis of the CATIE Schizophrenia Trial
Lilly Responds to the Cost-Effectiveness Analysis of the CATIE Schizophrenia Trial
HSMN NewsFeed - 6 Oct 2006
FDA Approves RISPERDAL(R) for Treatment of Irritability Associated with Autistic Disorder
FDA Approves RISPERDAL(R) for Treatment of Irritability Associated with Autistic Disorder
HSMN NewsFeed - 13 Apr 2006
Alkermes and Cephalon Receive FDA Approval of Vivitrol(TM) for the Treatment of Alcohol Dependence
Alkermes and Cephalon Receive FDA Approval of Vivitrol(TM) for the Treatment of Alcohol Dependence
HSMN NewsFeed - 17 Feb 2006
Alkermes Announces Submission of Complete Response to FDA for VIVITROL(TM) New Drug Application
Alkermes Announces Submission of Complete Response to FDA for VIVITROL(TM) New Drug Application
Additional items found! 40

Members Archive contains
40 additional stories matching:
risperidone
(Password required)
risperidone
(Password required)